Hypoxia-Inducible Factor-Proline Dioxygenases
"Hypoxia-Inducible Factor-Proline Dioxygenases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Dioxygenase enzymes that specifically hydroxylate a PROLINE residue on the HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. They are OXYGEN-dependent enzymes that play an important role in mediating cellular adaptive responses to HYPOXIA.
| Descriptor ID |
D064799
|
| MeSH Number(s) |
D08.811.682.690.416.617.500 D08.811.682.690.708.694.500
|
| Concept/Terms |
Hypoxia-Inducible Factor-Proline Dioxygenases- Hypoxia-Inducible Factor-Proline Dioxygenases
- Dioxygenases, Hypoxia-Inducible Factor-Proline
- Factor-Proline Dioxygenases, Hypoxia-Inducible
- Hypoxia Inducible Factor Proline Dioxygenases
- HIF Prolyl-4-Hydroxylases
- HIF Prolyl 4 Hydroxylases
- Prolyl-4-Hydroxylases, HIF
- Hypoxia-Inducible Factor-Proline Dioxygenase
- Dioxygenase, Hypoxia-Inducible Factor-Proline
- Factor-Proline Dioxygenase, Hypoxia-Inducible
- Hypoxia Inducible Factor Proline Dioxygenase
- HIF Prolyl-4-Hydroxylase
- HIF Prolyl 4 Hydroxylase
- Prolyl-4-Hydroxylase, HIF
|
Below are MeSH descriptors whose meaning is more general than "Hypoxia-Inducible Factor-Proline Dioxygenases".
Below are MeSH descriptors whose meaning is more specific than "Hypoxia-Inducible Factor-Proline Dioxygenases".
This graph shows the total number of publications written about "Hypoxia-Inducible Factor-Proline Dioxygenases" by people in this website by year, and whether "Hypoxia-Inducible Factor-Proline Dioxygenases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 3 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 3 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoxia-Inducible Factor-Proline Dioxygenases" by people in Profiles.
-
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 10; 104(4):655-680.
-
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
-
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
-
PHDs/CPT1B/VDAC1 axis regulates long-chain fatty acid oxidation in cardiomyocytes. Cell Rep. 2021 10 05; 37(1):109767.
-
Adhatoda Vasica attenuates inflammatory and hypoxic responses in preclinical mouse models: potential for repurposing in COVID-19-like conditions. Respir Res. 2021 Apr 06; 22(1):99.
-
Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. Int J Mol Sci. 2021 Mar 11; 22(6).
-
Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). Physiol Rep. 2020 06; 8(11):e14434.
-
Depletion of Endothelial Prolyl Hydroxylase Domain Protein 2 and 3 Promotes Cardiomyocyte Proliferation and Prevents Ventricular Failure Induced by Myocardial Infarction. Circulation. 2019 07 30; 140(5):440-442.
-
Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Cancer Res. 2019 05 01; 79(9):2327-2338.
-
Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun. 2018 12 21; 9(1):5426.